GFAP and Parkinson disease: Neuroinflammation is an important pathogenesis of PD, and we show that Akk has anti-inflammatory effects in both the striatum and hippocampus; specifically, in these brain regions, Akk treatment significantly reduced the expression of astroglia-specific marker (GFAP) and microglia-specific marker (Iba-1).